Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) saw unusually large options trading on Friday. Traders purchased 6,628 put options on the stock. This is an increase of 558% compared to the average volume of 1,008 put options.
Heartflow Stock Performance
Shares of NASDAQ HTFL traded up $1.62 during midday trading on Friday, hitting $46.25. 462,869 shares of the company’s stock traded hands, compared to its average volume of 1,610,075. The firm has a fifty day moving average of $51.82 and a 200 day moving average of $35.55. Heartflow has a 1 year low of $20.13 and a 1 year high of $60.65. The stock has a market capitalization of $4.06 billion, a price-to-earnings ratio of -50.26 and a beta of 2.50.
Heartflow (NASDAQ:HTFL – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.15. Heartflow had a negative net margin of 33.11% and a negative return on equity of 20.53%. The business had revenue of $72.86 million for the quarter. During the same quarter in the previous year, the business posted ($0.27) earnings per share. On average, equities analysts anticipate that Heartflow will post -0.75 earnings per share for the current year.
Analyst Ratings Changes
A number of analysts have commented on HTFL shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Heartflow in a report on Wednesday, November 4th. Stifel Nicolaus boosted their target price on Heartflow from $45.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, November 13th. JPMorgan Chase & Co. upped their target price on shares of Heartflow from $35.00 to $45.00 and gave the company an “overweight” rating in a research note on Friday, August 14th. Canaccord Genuity Group boosted their price objective on shares of Heartflow from $56.00 to $69.00 and gave the company a “buy” rating in a report on Friday, November 13th. Finally, UBS Group initiated coverage on shares of Heartflow in a research report on Wednesday, September 9th. They set a “neutral” rating and a $55.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Heartflow has a consensus rating of “Moderate Buy” and an average price target of $60.12.
View Our Latest Research Report on HTFL
Insider Buying and Selling at Heartflow
In other Heartflow news, insider Campbell Rogers sold 24,188 shares of the stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $46.39, for a total value of $1,122,081.32. Following the completion of the sale, the insider owned 64,424 shares in the company, valued at approximately $2,988,629.36. This trade represents a 27.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Vikram Verghese sold 29,714 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $50.06, for a total transaction of $1,487,482.84. Following the transaction, the chief financial officer directly owned 184,789 shares in the company, valued at approximately $9,250,537.34. The trade was a 13.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 323,936 shares of company stock valued at $16,355,191 in the last 90 days. Insiders own 7.70% of the company’s stock.
Hedge Funds Weigh In On Heartflow
Several institutional investors have recently added to or reduced their stakes in the company. Algert Global LLC bought a new position in shares of Heartflow in the 3rd quarter valued at about $2,960,000. Castleark Management LLC bought a new stake in Heartflow during the third quarter worth approximately $4,713,000. Virtu Financial LLC bought a new stake in shares of Heartflow in the 3rd quarter valued at approximately $1,028,000. Allworth Financial LP raised its holdings in Heartflow by 56.5% during the 3rd quarter. Allworth Financial LP now owns 828 shares of the company’s stock valued at $41,000 after buying an additional 299 shares during the period. Finally, Entropy Technologies LP lifted its position in Heartflow by 7.1% in the third quarter. Entropy Technologies LP now owns 10,156 shares of the company’s stock worth $505,000 after buying an additional 672 shares during the last quarter.
Latest Heartflow News
Investors following HTFL have been watching these news items:
- Positive Sentiment: Heartflow’s latest reported quarter showed a narrower-than-expected loss: EPS was negative $0.03 versus analysts’ expected negative $0.18, on revenue of $72.86 million. Analysts’ average rating was reported as “Moderate Buy,” with an average price target of $60.12. These are supportive context, though not new developments from today. Heartflow stock report
- Negative Sentiment: Insider Campbell Rogers’ reported sales include 16,918 shares at an average $24.40, as well as additional sales reported in October and November. Repeated selling can weigh on investor sentiment, although the transactions were conducted under a pre-arranged Rule 10b5-1 plan. Heartflow insider sale report
About Heartflow
HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.
Further Reading
- Five stocks we like better than Heartflow
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
- Apple’s Rare Samsung Memory Plan Could Solve One Problem and Create Another
- Palo Alto Networks’ Q1 Beat Gives Its Stock Rally Another Reason to Run
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
